Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A new study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients.
The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.
The nervous system is made up of diverse cells that arise from progenitors in a specific time-dependent pattern. In a new study, researchers have uncovered the molecular players involved and how the timing is controlled.
New research by National Eye Institute (NEI) investigators shows that while microsaccades seem to boost or diminish the strength of the brain signals underlying attention, eye movements are not drivers of those brain signals.
University of Pennsylvania researchers have developed a gene therapy that restores dim-light vision in dogs with a congenital form of night blindness, offering hope for treating a similar condition in people.
Researchers at the University of California, Berkeley, have found that a drug once widely used to wean alcoholics off of drinking helps to improve sight in mice with retinal degeneration.
Biomedical engineering and optical sciences professor DK Kang is developing a way to diagnose and treat corneal ulcers that's eight times cheaper and 20 times faster than today's gold standard.